N/A N=274 Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
Ileus
Primary: Measure of Improvement Over the Standard — 4.97; 3.98 Days in the hospital
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5,982 Comparative Effectiveness of Oral Anticoagulants
Atrial Fibrillation
Primary: Incidence Rate of Stroke — 29.09; 31.59 events per 1000 person years
N/A N=8 Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease
Wilson Disease
Primary: ALT — 41.38 U/L
Phase 4 N=47 Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12 — -6.0 mmHg
Phase 3 N=1,090 Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain. — 1.0; 0.7 units on a scale
Phase 4 N=1,697 Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
Surgical Site Infection
Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…
Phase 2 N=176 Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.
Medication Adherence
Primary: Self-efficacy - 8 Item Measure Taps Into Key Concepts Associated With Confidence for Managing Opioid Medications — 28.1081; 27.0563; 29.7143; 28.3224 units on a scale
Phase 3 N=488 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.9; 37.4; 32.1 percentage of participants — p=0.0060
N/A N=177 Post-market Study to Capture Information Regarding Performance of Lyric2
Hearing Loss
Primary: Immediate Refit Upon Device Removal — 78; 93 percentage of ears
Phase 2 N=203 Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
Postoperative Pain
Primary: Total Morphine Consumption in the First 24 Hours Following Postoperative Study Drug Treatment — 21.9; 17.6; 13.9; 19.8 mg — p=<0.05
Phase 3 N=87 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia in Remission · Acute Myeloid Leukemia in Remission · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 65; 54 percentage of participants — p=.09
Phase 4 N=132 Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care
Heart Failure
Primary: Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml — 38.5; 34.8 percentage of participants
Phase 2 N=497 Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women
Influenza
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) — 1; 0; 2; 1 participants
Phase 2 N=17 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Prostatitis · Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Global Response Assessment — 2 participants